Biogen Inc
Change company Symbol lookup
Select an option...
BIIB Biogen Inc
GRNH Greengro Technologies Inc
CLX Clorox Co
COP ConocoPhillips
FBP First Bancorp
PTCT PTC Therapeutics Inc
ROKU Roku Inc
WORK Slack Technologies Inc
ARKW ARK Next Generation Internet ETF
SPOT Spotify Technology SA
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Closing Price
$275.84
Day's Change
-4.45 (-1.59%)
Bid
--
Ask
--
B/A Size
--
Day's High
282.60
Day's Low
275.43
Volume
(Heavy Day)
Volume:
1,765,034

10-day average volume:
1,347,475
1,765,034
Latest Earnings Beat Consensus (Q3 ending 09/2020)Next Earnings Announcement
Q3
Announced October 21, 2020
$8.84Q3 Consensus
of 27 analysts
$8.04Difference from
consensus
9.05%
Q4 Earnings
will announce
(Unconfirmed) February 3, 2021

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

BIIB's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.